Tell us how you will advise your patients with chronic gastrointestinal illnesses about whether they should receive the COVID-19 vaccine when it becomes available to them.
Tell us how you will advise your patients with chronic gastrointestinal illnesses about whether they should receive the COVID-19 vaccine when it becomes available to them.
Created by 4 leading organizations, the recommendations are for gastroenterologists and gastroenterology care providers at institutions and practices that provide endoscopy and outpatient gastrointestinal services.
Created by 4 leading organizations, the recommendations are for gastroenterologists and gastroenterology care providers at institutions and practices that provide endoscopy and outpatient gastrointestinal services.
Gastroenterology Consultant published content on various topics throughout 2019. Which topic do you want to see more of this year? Take our poll to voice your opinion!
Gastroenterology Consultant published content on various topics throughout 2019. Which topic do you want to see more of this year? Take our poll to voice your opinion!
Patients with digestive diseases experience various iterations of symptoms and experiences, but generally accrue significant financial burden, research shows.
Patients with digestive diseases experience various iterations of symptoms and experiences, but generally accrue significant financial burden, research shows.
Patients with digestive diseases experience various iterations of symptoms and experiences, but generally accrue significant financial burden, research shows.
Patients with digestive diseases experience various iterations of symptoms and experiences, but generally accrue significant financial burden, research shows.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
Is terminal ileum resection in patients with Crohn’s disease associated with colorectal cancer risk? See what recent research found by taking our quiz.
Is terminal ileum resection in patients with Crohn’s disease associated with colorectal cancer risk? See what recent research found by taking our quiz.
Is there any association between esophageal disorders of gut-brain interaction and refractory reflux symptoms? Test your knowledge with our quick quiz!
Is there any association between esophageal disorders of gut-brain interaction and refractory reflux symptoms? Test your knowledge with our quick quiz!
A prospective study reveals that more than 70% of patients with proven gastroesophageal reflux disease and refractory symptoms also exhibit features of esophageal disorders of gut-brain interaction.
A prospective study reveals that more than 70% of patients with proven gastroesophageal reflux disease and refractory symptoms also exhibit features of esophageal disorders of gut-brain interaction.
The TEMPO trial investigated techniques to improve return rates for fecal immunochemical tests for colorectal cancer. Find out what worked best by taking our quick quiz!
The TEMPO trial investigated techniques to improve return rates for fecal immunochemical tests for colorectal cancer. Find out what worked best by taking our quick quiz!
Research has shown that several social determinants of health (SDOH) are associated with the prevalence of metabolic-associated steatotic liver disease. What has been identified as the most consistent associated SDOH?
Research has shown that several social determinants of health (SDOH) are associated with the prevalence of metabolic-associated steatotic liver disease. What has been identified as the most consistent associated SDOH?
Patients with digestive diseases experience various iterations of symptoms and experiences, but generally accrue significant financial burden, research shows.
Patients with digestive diseases experience various iterations of symptoms and experiences, but generally accrue significant financial burden, research shows.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A real-world cohort study found that patients with MASLD and type 2 diabetes who were not using GLP-1 RAs had a signficantly higher rate of hepatic complications compared to patients receiving GLP-1 therapy.
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
A new study adds to growing evidence that sexual and reproductive health issues are common yet frequently overlooked among younger colorectal cancer survivors.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
